Efanesoctocog alfa is a Fusion Protein owned by Sanofi, and is involved in 6 clinical trials, of which 3 were completed, 2 are ongoing, and 1 is planned.
Efanesoctocog alfa acts as coagulation factor VIII replacement therapy. Hemophilia is caused by the failure to produce certain proteins required for blood clotting, factor VIII (hemophilia A). In response to injury, coagulation factor VIII is activated and separates from von Willebrand factor. Factor VIII is a co-factor for activated factor IX, accelerating the conversion of factor X to activated factor X (factor Xa). Activated factor X converts prothrombin into thrombin. Thrombin then converts fibrinogen into fibrin and a clot can be formed. The drug candidate is a recombinant factor VIII fusion protein which replaces the deficient coagualnt factor VIII and facilitates in effective hemostasis.
The revenue for Efanesoctocog alfa is expected to reach a total of $7.4bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Efanesoctocog alfa NPV Report.
Efanesoctocog alfa Overview
Efanesoctocog alfa (BIVV-001) (rFVIIIFc-XTEN-vWF fusion molecule) is under development for the treatment of hemophilia A and Von Willebrand's Disease. FVIII is a glycoprotein procofactor. The drug candidate is administered through intravenous route. The drug candidate is a recombinant coagulation factor VIII Fc-Von Willebrand factor-XTEN fusion protein. It is developed based on XTEN technology. BIVV-001 acts by targeting coagulation factor VIII.
Swedish Orphan Biovitrum Overview
Swedish Orphan Biovitrum (Sobi) is an integrated biopharmaceutical company. It focuses on the development of products for the treatment of a few rare diseases. The company specializes in biotechnology with prime capabilities in protein biochemistry and biologics manufacturing. Its product portfolio focuses on hemophilia, immunology, specialty care, inflammation and genetic and metabolic diseases. The company also provides innovative treatment for conditions such as amyotrophic lateral sclerosis (ALS) and Hemophilia A. Sobi also manufactures and markets specialty products for rare diseases for partner companies. The company has operational presence in Europe, the Middle East, North America, Russia, and Asia. Sobi is headquartered in Stockholm, Sweden.
The company reported revenues of (Swedish Krona) SEK15,529 million for the fiscal year ended December 2021 (FY2021), an increase of 1.8% over FY2020. In FY2021, the company’s operating margin was 24%, compared to an operating margin of 31.6% in FY2020. In FY2021, the company recorded a net margin of 17.3%, compared to a net margin of 21.3% in FY2020. The company reported revenues of SEK3,999 million for the third quarter ended September 2022, an increase of 3.2% over the previous quarter.
Quick View – Efanesoctocog alfa
|Highest Development Stage|